MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

5.67 2.72

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.47

Max

5.68

Galvenie mērījumi

By Trading Economics

Ienākumi

42M

-100K

Pārdošana

-15M

196M

Peļņas marža

-0.051

Darbinieki

2,700

EBITDA

-12M

-14M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+55.68% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-829M

488M

Iepriekšējā atvēršanas cena

2.95

Iepriekšējā slēgšanas cena

5.67

Ziņu noskaņojums

By Acuity

50%

50%

157 / 376 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. jūl. 15:46 UTC

Galvenie tirgus virzītāji

BitMine Shares Fall After Closing of $250 Million Private Placement

2025. g. 9. jūl. 23:44 UTC

Tirgus saruna

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

2025. g. 9. jūl. 23:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 9. jūl. 23:42 UTC

Tirgus saruna

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

2025. g. 9. jūl. 22:59 UTC

Tirgus saruna

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

2025. g. 9. jūl. 22:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 9. jūl. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 9. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. jūl. 20:26 UTC

Peļņas

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

2025. g. 9. jūl. 19:18 UTC

Tirgus saruna

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

2025. g. 9. jūl. 19:03 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

2025. g. 9. jūl. 18:31 UTC

Tirgus saruna

Some Fed Officials Supported Considering July Cut -- Market Talk

2025. g. 9. jūl. 17:07 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk -2-

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 9. jūl. 16:14 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 9. jūl. 16:14 UTC

Tirgus saruna

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

2025. g. 9. jūl. 16:14 UTC

Iegādes, apvienošanās, pārņemšana

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

2025. g. 9. jūl. 16:12 UTC

Tirgus saruna

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

2025. g. 9. jūl. 16:08 UTC

Tirgus saruna

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

2025. g. 9. jūl. 15:31 UTC

Galvenie tirgus virzītāji

BitMine Shares Fall After Closing of $250M Private Placement

2025. g. 9. jūl. 15:31 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

2025. g. 9. jūl. 15:27 UTC

Tirgus saruna

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

2025. g. 9. jūl. 14:36 UTC

Iegādes, apvienošanās, pārņemšana

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

2025. g. 9. jūl. 14:31 UTC

Iegādes, apvienošanās, pārņemšana

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

2025. g. 9. jūl. 14:26 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 9. jūl. 14:26 UTC

Tirgus saruna

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

55.68% augšup

Prognoze 12 mēnešiem

Vidējais 8.64 USD  55.68%

Augstākais 18 USD

Zemākais 4 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

13 ratings

4

Pirkt

7

Turēt

2

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 7.55Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

157 / 376 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.